Abirapro 250 mg is identified as a tablet containing 250 mg of abiraterone acetate. Product listings identify Glenmark Pharmaceuticals Ltd. as the manufacturer/marketer.
Abiraterone acetate is a prodrug. After administration it is converted to abiraterone, which inhibits CYP17A1 and suppresses androgen biosynthesis.
Product identity
| Attribute | Information |
| Product | Abirapro 250 mg |
| Generic/active substance | Abiraterone acetate |
| Strength | 250 mg |
| Form | Tablet |
| Route | Oral |
| Drug class | Androgen biosynthesis inhibitor |
| Main therapeutic area | Prostate cancer |
| Reference product | Zytiga |
| Product manufacturer/marketer | Glenmark Pharmaceuticals Ltd. |
| Specific marketing authorization | [Information requires verification] |
Abiraterone acetate versus abiraterone
The terms should not be used interchangeably without explanation. Abiraterone acetate is the administered prodrug. Abiraterone is the active form generated after conversion in the body. The active molecule inhibits CYP17A1, reducing androgen synthesis.
Reference product
Zytiga is the established reference product containing abiraterone acetate. The original U.S. development and regulatory history involved Cougar Biotechnology and Johnson & Johnson’s oncology operations.
Abirapro may contain the same active pharmaceutical ingredient but should not automatically be described as identical to Zytiga. Manufacturing processes, excipients, packaging, authorization and product-specific characteristics can differ.
Why corticosteroid therapy is used
CYP17 inhibition decreases androgen production but also alters steroid pathways upstream of cortisol. This can increase mineralocorticoid activity. Prednisone or prednisolone is used with abiraterone in the labeled treatment regimens to help manage this pharmacologic effect.